trending Market Intelligence /marketintelligence/en/news-insights/trending/wyzojglcdatme7uw0ubmyg2 content esgSubNav
In This List

Nuformix adds nonexecutive director to board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Nuformix adds nonexecutive director to board

Nuformix PLC appointed Christopher Blackwell as a nonexecutive director of the company.

Blackwell served as the CEO of Vectura Group PLC from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion, Nuformix said in a statement.

Cambridge, U.K.-based Nuformix uses cocrystal technology to improve small molecule drugs.

Blackwell will assist the company as it develops its NXP002 programme for the treatment of fibrosis.